Skip to main content

Optimal Choice Between Chemotherapy and Immunotherapy for Leukemia Treatment Depends on Individual Patients’ Patho-physiological State

  • Conference paper
  • First Online:
Progress in Computing, Analytics and Networking

Part of the book series: Advances in Intelligent Systems and Computing ((AISC,volume 710))

  • 1688 Accesses

Abstract

Chemotherapy is the firsthand choice of any cancer therapy including leukemia. However, immunosuppression is commonly seen in leukemic patients. So for the management of leukemia, cytokine-based immunotherapy is also suggested as either a combination therapy along with the conventional chemotherapy or alone. However, therapy is applied on individual patients on the basis of evidence-based medicine, i.e., population-based statistical analysis and/or on the basis of clinicians’ personal experience. Here, we propose an analytical rationality for therapeutic selection among these two options. Our simulation runs suggest that choice would be based on individual patients’ patho-physiological state like immunity profile or another hematological status. Simulation runs also suggest that in some cases chemotherapy may bring detrimental effect and direct immunotherapy would be beneficial for long-term successful therapeutic outcome. Further, this model helps in the optimization of cytokine-based immunotherapy protocol.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. DeLsi, C., Rescigno, A.: Immnue surveillance and neoplasia 1 a minimal mathematical model. Bulletin of Mathematical Biology. 39 (1977) 201–221.

    Google Scholar 

  2. Grossman, B.G.: Tumour escape from immune elimination J Theor Biol 83 (1980) 267–296.

    Google Scholar 

  3. Kustnetsov, V.A., Malakin, A.M., Taylor, M.A., Perelson, A.S.: Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis, Bull. Math. Bio. 56 (1994) 295–321.

    Google Scholar 

  4. Preziosi, L.: From population dynamics to modeling the competition between tumors and immune system Mathl. Comput. Modelling. 23 (1996) 135–152.

    Google Scholar 

  5. Michor, F., Beal, K.: Improving cancer treatment via mathematical modeling of population dynamics. Cell. 163 (2015) 1059–1063.

    Google Scholar 

  6. Bellomo, N., Forni, G.: Dynamics of tumor interaction with the host immune system, Mathl. Comput. Modelling 20 (1994) 107–122.

    Google Scholar 

  7. Kolev, M.: Mathematical modeling of the competition between tumors and immune system considering the role of the antibodies. Mathl. Comput. Modelling. 37 (2003) 1143–1152.

    Google Scholar 

  8. Kim, P.S., Lee, P.P., Levy, D.: Dynamics and potential impact of the immune response to chronic myelogenous leukemia, PLoS Comp Biol. 4 (2008):e1000095.

    Google Scholar 

  9. Kim, P.S., Lee, P.P., Levy, D.: A PDE model for imatinib-treated chronic myelogenous leukemia. Bull. Math. Biol. 70 (2008) 1994–2016.

    Google Scholar 

  10. Foo, J., Drummond, M.W., Clarkson, B., Holyoke, T., Michor, F.: Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Computational Biology. 5 (2009), e10000503.

    Google Scholar 

  11. Dhar, P.K., Mukherjee, A., Majumder, D.: Difference delay equation-based analytical model of hematopoiesis. Aut. Contrl. Physiol. State. Func. 1 (2012) 1–11.

    Google Scholar 

  12. Dhar, P.K., Majumder, D.: Development of the analytical model for the assessment of the efficiencies of different therapeutic modalities in leukaemia. J. Comp. Syst. Biol. 1 (2015) 1–45.

    Google Scholar 

  13. Michor, F., Hughes, T.P., Iwasa, Y., Branford, S., Shah, N.P., Sawyers, C.L., Nowak, M.A.: Dynamics of chronic myeloid leukemia. Nature 435 (2005) 1267–1270.

    Google Scholar 

Download references

Acknowledgements

PKD is pursuing Ph.D. from Jadavpur University. All authors acknowledge the logistic support provided by Society for Systems Biology & Translational Research.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Durjoy Majumder .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

Dhar, P.K., Naskar, T.K., Majumder, D. (2018). Optimal Choice Between Chemotherapy and Immunotherapy for Leukemia Treatment Depends on Individual Patients’ Patho-physiological State. In: Pattnaik, P., Rautaray, S., Das, H., Nayak, J. (eds) Progress in Computing, Analytics and Networking. Advances in Intelligent Systems and Computing, vol 710. Springer, Singapore. https://doi.org/10.1007/978-981-10-7871-2_62

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7871-2_62

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7870-5

  • Online ISBN: 978-981-10-7871-2

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics